Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis

Background At present, there are no approved pharmacological treatments for people at clinical high risk for psychosis (CHR-P). We sought to assess the acceptability of cannabidiol (CBD): a promising candidate treatment for this population. Methods CHR-P individuals completed a survey which assessed their views on the acceptability of CBD, its expected effectiveness and side effects, and on formulation preferences. Results The sample comprised 55 CHR-P individuals (24.3 [19-34] years and 69% female). Most (91%) were familiar with CBD, and had previously used cannabis (64%), and around half (42%) had tried over-the-counter CBD. 75% (95%CIs: 64-86%) were willing to take CBD as an intervention for mental health problems. Most participants anticipated fewer side effects with CBD than with existing medications, and preferred tablet or capsule formulations over liquids. Discussion CBD is perceived as a highly acceptable treatment among CHR-P individuals.

Authors

Institutions

Publication Details

Journal
Frontiers in Psychiatry
Published
2026-04-27
DOI
https://doi.org/10.3389/fpsyt.2026.1823912
Primary Topic
Cannabis and Cannabinoid Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis

Phoebe Wallman, Andrés Estradé, Peter J. Uhlhaas, Umberto Provenzani et al.
Frontiers in Psychiatry
Cannabis and Cannabinoid Research
article

Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis

Phoebe Wallman, Andrés Estradé, Peter J. Uhlhaas, Umberto Provenzani, Paolo Fusar‐Poli, Stefano Damiani, Matilda Azis, Amedeo Minichino, Edward Chesney, Shubhi Agarwala, Antonio Melillo, Dominic Oliver, Olivia Hunt, Philip McGuire
article en

Abstract

Background At present, there are no approved pharmacological treatments for people at clinical high risk for psychosis (CHR-P). We sought to assess the acceptability of cannabidiol (CBD): a promising candidate treatment for this population. Methods CHR-P individuals completed a survey which assessed their views on the acceptability of CBD, its expected effectiveness and side effects, and on formulation preferences. Results The sample comprised 55 CHR-P individuals (24.3 [19-34] years and 69% female). Most (91%) were familiar with CBD, and had previously used cannabis (64%), and around half (42%) had tried over-the-counter CBD. 75% (95%CIs: 64-86%) were willing to take CBD as an intervention for mental health problems. Most participants anticipated fewer side effects with CBD than with existing medications, and preferred tablet or capsule formulations over liquids. Discussion CBD is perceived as a highly acceptable treatment among CHR-P individuals.

Frontiers in PsychiatryVol. 17
King's College London (GB), South London and Maudsley NHS Foundation Trust (GB), University of Pavia (IT), Oxford Health NHS Foundation Trust (GB), Centre for Mental Health (GB), University of Oxford (GB), Health Biomed (China) (CN), University of Campania "Luigi Vanvitelli" (IT), University of Birmingham (GB)
Wellcome Trust, National Institute for Health and Care Research, NIHR Maudsley Biomedical Research Centre
Good health and well-being
Openalex Percentile: Top 12%
Cannabis and Cannabinoid Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.